Is Telomir Pharmaceuticals, Inc. Common Stock (TELO) overvalued? · $86.0M cap
Telomir Pharmaceuticals, Inc. Common Stock (TELO) is a biotechnology company listed on NASDAQ.
This page asks whether Telomir Pharmaceuticals, Inc. Common Stock (TELO) looks expensive on cached numbers — not a short thesis.
No cached income statement for TELO, so there is no earnings base to call rich or cheap.
TELO currently screens at market cap $86.0M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next TELO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the TELO stock page for the full model, not this heading.
Not investment advice.